Raise closed, search for fresh raises on Seedstage

Henderson, NV

Revolutionizing the treatment of osteoporosis through innovative regenerative technology.

• Mission: Transforming the treatment of osteoporosis and osteopenia through innovative regenerative technology that revitalizes bone health and reduces fracture risk.  
• Innovation: Uses a patented organic compound to stimulate natural bone regeneration, targeting the patient’s own bone-growing cells to promote healthy bone density without systemic side effects.  
• Targeted Treatment: Focuses on local application to areas of low bone density, offering a precision approach to bone health that specifically enhances mineral density in weakened bones.  
• Regulatory Success: Has successfully navigated the FDA clearance process for maxillofacial applications and is now expanding to treat skeletal conditions, positioning it as a leader in bone health innovation.  
• Preventative Focus: Aims to restore bone density before deterioration leads to fractures, offering a preventative solution for osteoporosis and frailty associated with aging.  
• Future Vision: Plans to establish specialized facilities for treating skeletal diseases, bridging the gap between scientific advancements and clinical practice to improve global health outcomes.

OsNovum is dedicated to transforming the treatment of osteoporosis and osteopenia through its innovative regenerative technology aimed at revitalizing bone health. With a mission to address the needs of the over 200 million people affected by osteoporosis globally, OsNovum’s patented organic compound stimulates the body’s natural bone regeneration processes.

This groundbreaking solution is designed to be applied locally to areas of low bone density, directly targeting the patient’s own bone-growing cells, thus promoting the growth of dense, healthy bone without the systemic side effects commonly associated with traditional treatments. The company has successfully navigated the FDA clearance process for maxillofacial applications and is now focused on adapting this technology for skeletal use.

With plans to establish specialized facilities for treating skeletal diseases, OsNovum aims to make cutting-edge scientific advancements accessible to patients. The fundraising initiative seeks to secure the necessary resources to complete the regulatory pathway and bring this revolutionary treatment to market, ultimately improving the quality of life for millions suffering from bone-related conditions.

By investing in OsNovum, stakeholders can contribute to a significant shift in osteoporosis treatment and enhance global health outcomes.

Company Info

OsNovum develops precision regenerative therapies to improve bone health and prevent fractures in osteoporosis patients.

OsNovum is focused on developing precision regenerative therapies aimed at improving bone health for patients suffering from osteoporosis. The company utilizes FDA-cleared technology that has a history of regenerating maxillofacial bone, applying this approach to treat weak and frail bones. By targeting the body’s own bone-growing cells, or osteoblasts, OsNovum’s patented material enhances mineral density and vitality of bone, reducing the risk of fractures. Their goal is to restore bone density before deterioration leads to breaks, offering a preventative solution to osteoporosis. OsNovum aims to transform the treatment landscape for osteoporosis by establishing specialized facilities dedicated to skeletal disease, bridging the gap between scientific research and clinical practice. The company recognizes the need for better education among physicians regarding osteoporosis and its treatment, as well as the interconnectedness of muscle and bone health. Through their innovative approach, OsNovum aspires to improve patients’ quality of life and expand life expectancy by addressing frailty associated with aging.